Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer

Overview of attention for article published in Experimental Hematology & Oncology, January 2017

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 14 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 5 X posts from 3 X users, with an upper bound of 3,179 followers.

@promegauk https://t.co/AD7wOsqE8c

20 Jun 2018

Reply Repost Favourite

Open Access UCL Research: Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer https://t.co/5RqX63nC4I

20 Jun 2018

Reply Repost Favourite

Dabrafenib & trametinib activity in a pt w/ BRAF V600E mt & MSI high metastatic endometrial cancer w/ @BioMedCentral https://t.co/XN5adC1sy4

13 Jan 2017

Reply Repost Favourite

Dabrafenib & trametinib activity in a pt w/ BRAF V600E mt & MSI high metastatic endometrial cancer w/ @BioMedCentral https://t.co/XN5adC1sy4

12 Jan 2017

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.